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A low-frequency inactivating AKT2 variant enriched in the Finnish population is associated 
with fasting insulin levels and type 2 diabetes risk.  
Short title: AKT2 coding variant affects fasting insulin levels  
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Supplementary Notes 
SUPPLEMENTARY NOTE 1: SUMMARY OF ASSOCIATION RESULTS AT KNOWN AND NOVEL LOCI. 
The exome-wide single variant association results are displayed in Supplementary Table 2. We first 
partitioned the significant (P <5 × 10-7) and suggestive (P <5 × 10-6) single variant association results into two 
sets: variants in previously reported associated regions [Supplementary Table 2A] and variants with 
potentially novel association signals [Supplementary Table 2B].  
Of the 57 loci with common variants associated with FG or FI in multiple ancestries4,5,10,58,72-80, twenty-one 
regions contained significant or suggestive association signals in our analysis. Of the seven regions harboring 
significant associations with non-synonymous variants, five (GCKR, G6PC2, SLC30A8, PCSK1, and GLP1R) 
were described previously by our group10, where, when possible, conditional analyses and functional 
experiments are utilized to illuminate functional transcripts. In the MADD locus, a missense variant ACP2 
p.Arg29Gln showed significant association with FG levels (P = 1.91 x 10-7, MAF = 38%). This variant is in low 
LD (r2 = 0.138) with the reported variant, rs7944584 (P = 2.62 x 10-11, MAF = 39%), but after conditioning on 
rs7944584 the association was not significant (P = 0.003). An additional association with a low-frequency 
variant was observed at the MTNR1B locus. A variant upstream of MTNR1B, rs7950811, (effect = 0.057; P = 
6.8 x 10-11), has a MAF of 4.5% and in low LD with the index SNP, rs10830963 (r2 = 0.002), in 1000 Genomes 
data121. After conditioning on the index SNP, the association of rs7950811 with FG remained significant (P = 
3.07 x 10-7). For FI, five regions contained significant or suggestive association signals. All of the insulin-
associated variants were common with MAF > 25%. Two of these regions, the GCKR and GRB14/COBLL1 
loci, harbor significant missense variants and were previously described10. 
Association results at previously reported variants from genome-wide association studies are presented in 
Supplementary Table 2C. Of the 68 previously published common variant associations with FG and FI, we 
were able to carry out association tests at 36 FG and 16 FI variants. Thirty of the FG association loci showed P 
< 0.05, with 100 % having a consistent direction of effect. Thirteen FI associated loci had P < 0.05, with 100% 
demonstrating a consistent direction of effect. 
Potentially novel association signals 
We observed five and seven variants passing suggestive level of significance for FI and FG, respectively 
[Supplementary Table 2B]. As this analysis focused on coding variation, we took the three coding variants 
forward to a replication analysis in four independent Finnish studies (N = 5,747)82-85. The p.Pro50Thr variant in 
AKT2 was present and well-imputed in the 1000 Genomes reference panel (imputation score: 0.886 to 0.957). 
The correlation between imputed and directly genotyped genotypes was high (r2 > 0.88), and the association of 
this variant with FI levels replicated, (Preplication = 0.00054, N = 5,747) resulting in a combined (discovery and 
replication) sample P value of 9.98 × 10-10  [Supplementary Table 2E]. MMEL1 p.Glu323Gln, which has a 
MAF of only 0.2% (seven minor allele carriers in the HBCS subset), was poorly imputed and not tested for 
	  	  
association (imputation score: 0.718 to 0.945, r2 = 0.57). TP53BP1 p.Thr1278Ile was not observed in the 
studies. 
Summary of exome-wide significant gene based association results 
The suggestive and significant gene based association signals from each ancestry group in the exome 
sequencing data and the exome chip data, as well as combined results, are displayed in Supplementary 
Table 2D. The AKT2 gene based association with FI is described in the main text. 
In gene-based tests using the PTV+NSbroad mask, NDUFAF1 was significantly associated with FI levels (PBurden 
= 1.10 × 10-6). This association was driven by a single missense variant (p.His309Asp, rs199599633, P = 9.3 × 
10-5, N = 1,673) that was not associated with FI levels in exome array data (P = 0.018, N = 19,569). NADH 
dehydrogenase (ubiquinone) complex I, assembly factor 1, or NDUFAF1, encodes for a complex I assembly 
factor protein, which is part of the first step of the respiratory chain. Mutations in both copies of this gene are 
reported to cause mitochondrial complex I deficiency, which manifests as cardioenphalomypathy or fatal 
hypertrophic cardiomyopathy while heterozygous parents were reported as healthy122,123.  
Additionally, a third gene, GIMAP8, was associated with FG levels in the PTV-only mask (PBurden = 2.30 × 10-6). 
This association was driven by singleton and doubleton variants. This gene encodes a GTPase of the 
immunity-associated protein family124 	    
	  	  
SUPPLEMENTARY NOTE 2: EXPRESSION PROFILE OF AKT2 
To gain further insights into the tissues relevant for AKT2 function we explored gene and transcript expression 
patterns of AKT2 (ENSG00000105221) from multiple (N = 44) human tissues using RNA sequencing (RNA-
seq) data from the Genotype Tissue Expression (GTEx) Project108. 
In the GTEx data AKT2 is ubiquitously expressed [Supplementary Fig. 10A,B]; the gene is present in all the 
available tissues (median expression across individuals RPKM125 (reads per kb per million reads) > 7 in all 
tissues, [Supplementary Table 4] and in all individuals, in agreement with previous studies examining AKT2 
expression via RT-PCR, Western blot, and Northern Blot analysis37,38,126,127, and documented essential role of 
AKT isoforms in biological processes throughout the body39. No enrichment of AKT2 expression is present in 
insulin sensitive tissues (i.e. pancreas, skeletal muscle, adipose tissue (both subcutaneous and visceral), liver 
and kidney cortex) via RNA sequencing as proposed in mouse and rat models, however, this is consistent with 
previous examination of AKT2 mRNA in human tissues38,126-128. This GTEx RNA sequencing data does not 
address insulin-sensitive tissue enrichment seen at the level of AKT2 protein, yet in general mRNA levels 
correlate with protein abundance129-131.  
AKT2 has multiple alternatively spliced transcripts, yet little is known of their specific roles, and therefore we 
investigated which of the transcripts are the most abundant and which tissues these are active in Gencode 
version 12 used in the gene and transcript annotations lists 28 AKT2 transcripts and 17 of these transcripts are 
expressed (mean RPKM > 1) in at least one of the studied tissues [Supplementary Fig. 10C,D]. However, 
majority of the expression appears to be due to three AKT2 transcripts: AKT2-004 (processed transcript) and 
AKT2-001 (protein-coding) that span the full length of the gene, and AKT2-008 (protein-coding), which does 
not include the downstream exons. Together these three transcripts constitute on average 44% (range 18-
65%) of AKT2 expression in the GTEx tissues. The two longer AKT2 transcripts, AKT2-004 and AKT2-001, 
follow similar expression pattern to the gene, while the shorter one, AKT2-008, shows more specific pattern of 
expression being most expressed in uterus, kidney cortex and esophagus mucosa. 
The exon containing the p.Pro50Thr variant is included in 14 out of 28 expressed transcripts (all the 28 AKT2 
transcripts are expressed at a detectable level in at least one individual in at least one tissue), including in all 
the three most highly expressed transcripts [Supplementary Fig. 10D]. The expression profile of the exon 
containing p.Pro50Thr is similar to the whole AKT2 gene with the tissues showing highest AKT2 expression 
generally having the higher levels of expression of the exon containing p.Pro50Thr [Supplementary Fig. 10B]. 
Notably, the exon is expressed in all tissues and all individuals, further suggesting that the exon likely encodes 
part of the protein integral for its function. 
Similarly to AKT2, the two other members of the AKT gene family, AKT1 and AKT3, are expressed in all the 
tissues available in the GTEx data with the exception of rather low expression of AKT3 in liver and whole 
blood. Of the three genes, AKT1 is generally the most and AKT3 the least abundant in all tissues. AKT2 is the 
	  	  
most highly expressed of the three homologs (P < 0.05 for all comparisons using one-sided paired Student’s t-
test and log2 transformed expression values) only in skeletal muscle, pituitary and cerebellum/cerebellar 
hemisphere, with the higher AKT2 expression being most pronounced in skeletal muscle [Supplementary Fig. 
11]. 
 	    
	  	  
SUPPLEMENTARY NOTE 3: PATHWAY ANALYSES 
Methods 
We used biological knowledge to test for enrichment of signal in pathways. Pathways and networks were 
selected from MSigDB132, which includes Gene Ontology, pathways from KEGG, Ingenuity, Reactome, and 
Biocarta; and the manually curated monogenic pathways previously considered. We carried out a two-stage 
enrichment analysis: step one calculates gene aggregation scores using a function of single variant statistics; 
and step two calculates gene set scores using a function of aggregation scores from each gene in the set. In 
step one, we make use of a range of gene aggregation functions, including the minimum p-value (or maximum 
Bayes’ factor) for single-variant association (within ancestry or trans-ethnic) in the gene (with correction for the 
number of variants in the gene). In step two, we apply a pre-ranked GSEA method132, which consists of a 
sensitive-improved Kolmogorov-Smirnov (random bridge) statistic, and which provides better correction of the 
null distribution for highly correlated gene sets (as we see for our hand curated gene sets). Additionally, we 
performed a biologically enhanced pathway analyses with DEPICT133, an integrative tool that we used to 
highlight enriched pathways and identify tissues/cell types where genes from associated loci are highly 
expressed. 
Gene set definitions: We assembled pre-defined, hand-curated lists to create four gene sets: “Monogenic All” 
(N = 81), including any gene with reported mutations that result in a disease or syndrome leading to either 
increased prevalence of diabetes or changes in glycemic traits. We further prioritized two subsets of genes, 
“Monogenic Glucose” (N = 41) and “Monogenic Insulin” (N = 37) including any gene with mutations leading to 
changes in respective glycemic traits as a primary feature. The list contains genes identified before September 
2013. The fourth gene set, “Insulin Receptor Signaling,” was created using Ingenuity Pathway Analysis (IPA) 
tools134 by merging the insulin receptor signaling, IGF-1 signaling, and PI3K/AKT signaling pathways and 
adding all downstream phosphylated substrates of AKT. 
Association Analysis: SKAT and burden tests were performed after aggregating functional variants 
(according to the previously described criteria) across all the genes in each gene set. Conditional analyses 
were performed using features implemented in RareMETALS67,68. 
Enrichment of association signals: Empirical enrichment for the number of gene based tests with P < 0.001 
and the number of single variant tests with P < 0.001 in each gene set was determined by first counting the 
number of tests below the threshold. For a particular gene set, let Nobserved denote the number of tests with P < 
0.001. A pool of similar genes was assigned to each gene in the gene set, according to the quartile of exon 
length and quintiles of the number of the nonsynonymous and synonymous variants in the gene. For each 
gene set, 1,000 matched gene sets were created. An empirical distribution of Ni (the number of tests with P < 
0.001 in matched set i) was constructed for each of the matched sets. The empirical enrichment P-value was 
calculated by observing the proportion of matched sets with Ni ≥ Nobserved. 
	  	  
Additional traits related to insulin resistance: We examined the single variant association of fasting 
adiponectin level (log-transformed, age, sex and BMI adjusted, and inverse-normalized), 2 hour glucose level 
(age, sex and BMI-adjusted, and inverse-normalized) and 2 hour insulin level (log-transformed, age, sex and 
BMI adjusted, and inverse-normalized) in these pathways using exome array data when available from the 
discovery cohorts (D2D2007, DPS, DRSEXTRA, FINRISK, FUSION, Health2008, Inter99, METSIM, ULSAM). 
Results 
To further assess the evidence of enriched signals in biologically related genes, we looked for enrichment 
across pathways using both hand curated and publically available pathways. This was conducted using 
GSEA132,135,136. While no gene-set was significant after multiple testing correction, there is enrichment for 
several pathways, including adipocytokine signaling, glucose transport, galactose metabolism, glycolysis and 
gluconeogenesis, and starch and sucrose metabolism pathways, all of which include both G6PC2 and G6PC. 
While the G6PC2 association with FG has previously been described 10, we note that G6PC mutations result in 
glycogen storage disorders137.  
Since AKT2 lies in the insulin receptor signaling pathway and AKT2 mutations are a known cause of both 
familial lipodystophy, severe insulin resistance and hypoglycemia 23-26 we next explored whether there was an 
enrichment of rare and low frequency variants in these gene sets (“Monogenic Genes,” and “Insulin Receptor 
Signaling Genes”) [Supplementary Table 8A]. First, we tested for global enrichment by aggregating all 
variants predicted to be deleterious using the annotation masks previously described for gene based testing 
(PTV-only, PTV+NSstrict, PTV+NSbroad, PTV+Missense)136. We found a significant enrichment of deleterious 
variants (protein truncating, splice site and non-synonymous) in the monogenic genes (P = 2 × 10-4) in exome 
array data [Supplementary Table 8B) but no such enrichment in an analysis of the exome sequencing data 
set (P = 0.87) [Supplementary Table 8C]. Conditional analyses demonstrated that in addition to AKT2 
p.Pro50Thr (P conditional on AKT2 p.Pro50Thr = 0.0017), seven additional top ranked variants contribute to 
this signal (P conditional on AKT2 p.Pro50Thr, CFTR p.Asp1270Asn, INSR p.Val1012Met, ZMPSTE24 
p.Arg178His, ZFP57 p.Arg178His, CFTR splice donor variant rs78756941 and PCNT p.Glu1785Lys jointly = 
0.0104) [Supplementary Table S8D,E]. No other novel associations were detected with the other gene sets 
and variant masks, although when comparing the effects of the burden tests across the four variant 
aggregation categories, we observed a positive trend of effect as we examined the category containing the 
least predicted deleterious (PTV+missense) to the most predicted deleterious (PTV-only), although the 
confidence intervals widen as the number of included variants decrease [Supplementary Fig. 13]. 
To find specific genes harboring an enrichment of association with either FG or FI levels, we next focused on 
association results from the monogenic genes, testing each set for empirical enrichment. We found that a gene 
implicated in congenital generalized lipodystrophy, CAV1138, showed enrichment of association with FG levels 
when considering the set of glucose-specific monogenic genes from the exome sequencing analysis 
(enrichment P = 0.03; CAV1 P = 1.9 × 10-4 with protein truncating and low-frequency missense variants and P 
	  	  
= 7.0 × 10-4 with protein truncating and predicted deleterious variants). Mutations in CAV1 are characterized by 
extreme insulin resistance and lipodystrophy 138 but in our data no association of CAV1 variants with FI levels 
was observed. We also observed a borderline enrichment for fasting insulin level with a gene-based burden 
test in the insulin receptor signaling pathway (enrichment P = 0.06; (PTGS2 burden P = 1.1 × 10-4 with protein 
truncating and low-frequency missense variants; [Supplementary Fig. 14, Table S9A,B). 
We further examined the association of three quantitative traits related to insulin resistance: fasting adiponectin 
level, and 2 hour glucose and 2 hour insulin levels after an oral glucose tolerance test. Besides a nominally 
significance Other than the AKT2 p.Pro50Thr allele association with 2 hour insulin level (Effect = 26% 
increase, 95% confidence interval = 16% - 38%, P = 7.86 × 10-8), no other associations were observed 
[Supplementary Fig. 14C]. 	    
	  	  
SUPPLEMENTARY NOTE 4: PRIMERS FOR FUNCTIONAL WORK 
The generation of the AKT2 allelic series was initiated by the production of pDONR223- AKT2 through PCR of 
the human AKT2 open reading frame with the integration of terminal attR sites using primers FWD: 5’ -
GGGGACAAGTTTGTACAAAAAAGTTGGCACCATGAATGAGGTGTCTGTCATC -3’ REV: 5’- 
GGGGACCACTTTGTACAAGAAAGTTGGCAACTCGCGGATGCTG -3’, and subsequent Gateway BP reaction 
into pDONR223 obtained from The Broad Institute Genetics Perturbation Platform. Site-directed mutagenesis 
was then performed to generate AKT2.E17K (AKT2.Lys17), AKT2.P50T (AKT2.Thr50), AKT2.R208K 
(AKT2.Lys208), AKT2.R274H (AKT2.His274), AKT2.R467W (AKT2.Trp467) with the following primers: 
• AKT2.E17K: FWD: 5'- GGCTCCACAAGCGTGGTAAATACATCAAGACCTGG -3' REV: 5'- 
CCAGGTCTTGATGTATTTACCACGCTTGTGGAGCC -3' 
• AKT2.P50T: FWD: 5'- AGGCCCCTGATCAGACTCTAACCCCCTTAAAC -3' REV: 5'- 
GTTTAAGGGGGTTAGAGTCTGATCAGGGGCCT -3' 
• AKT2.R208K: FWD: 5'- GTCCTCCAGAACACCAAGCACCCGTTCC -3' REV: 5'- 
GGAACGGGTGCTTGGTGTTCTGGAGGAC -3' 
• AKT2.R274H: FWD: 5'- GGGACGTGGTATACCACGACATCAAGCTGGA -3'REV3'REV: 5'- 
TCCAGCTTGATGTCGTGGTATACCACGTCCC -3' 
• AKT2.R467W: FWD: 5'- GGAGCTGGACCAGTGGACCCACTTCCC -3' REV: 5'- 
GGGAAGTGGGTCCACTGGTCCAGCTCC -3' 
C-terminal, V5-tagged lentiviral pLX304-AKT2.E17K, pLX304-AKT2.P50T, pLX304- AKT2.R208K, pLX304-
AKT2.R274H, and pLX304- AKT2.R467W were each generated by subsequent Gateway LR reactions with 
pDONR223-AKT2.E17K, pDONR223-AKT2.P50T, pDONR223-AKT2.R208K, pDONR223-AKT2.R274H, and 
pDONR223-AKT2.R467W, respectively, and pLX304 obtained from The Broad Institute Genetics Perturbation 
Platform. Control plasmid pLX304- empty vector was additionally acquired from The Broad Institute Genetics 
Perturbation Platform. 
 
  
	  	  
Supplementary Figures 
A. Fasting Plasma Glucose * 
 
B. Fasting Insulin 
 
C. Fasting Plasma Glucose 
 
D. Fasting Insulin 
  
Fig. S1. Manhattan and quantile-quantile (QQ) plots for exome-wide association analysis with FG (A 
and C) and FI levels (B and D). A. Manhattan plot for FI, B. Manhattan plot for FG, C. QQ plot for FI, D. QQ 
plot for FI. On the manhattan plots, variants within regions of known association  are colored in dark blue, and 
variants outside those regions are colored in gray. The red horizontal line in the manhattan plots represents the 
exome-wide significance threshold for single variant associations (P < 2.5 × 10-7). In the QQ plots the grey 
shaded area shows the 95% confidence interval. * For readability, the FG manhattan plot is truncated at –
log10(P) = 20, although variants in the G6PC2 region on chromosome 2 have –log10(P) values > 20. 
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Fig S2. QQ plots from the gene based association tests for FI and FG. Two tests were applied, SKAT (left 
column) and Burden (right column) to four annotation masks (PTV, PTV+NSBroad, PTV+NSStrict, PTV+Missense, 
see Methods for description). A. FI with variants in exome sequencing data set. B. FG with variants in exome 
sequencing data set. C. FI with variants in exome chip data set. The point deviating from the diagonal is the 
association test for AKT2; see Table S2a for association details. D. FG with variants in exome chip data set. 
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Fig. S3: Population structure and diversity indices of AKT2 protein in the exome sequencing data set. 
Each pie represents the frequency of different haplotypes, estimated from phased exome sequencing data in 
the five continental ancestries (grouped by study or country of origin). Significance of Tajima’s D and F‐
statistics (global FST, FIS, FIT, and pairwise FST (gray line), and within population FIS) are indicated with asterisk: 
* P-value < 0.05; ** P-value < 0.01; *** P-value < 0.001. S: Number of segregating sites; Na: expected number 
of alleles; Pi (π): Mean number of pairwise differences; Theta (θ): Watterson’s θ estimate; MK: McDonald-
Kreitman test. African-American: AJ – Jackson Heart Study, AW – Wake Forest School of Medicine Study; 
East-Asian: EK – Korea Association Research Project, ES – Singapore Diabetes Cohort Study and Singapore 
Prospective Study Program; European: UA – Ashkenazi (US, Israel), UB – UKT2D Consortium (UK) , UF 
(Finland) – Metabolic Syndrome in Men Study, Finland-United States Investigation of NIDDM Genetics 
(FUSION) Study, Malmo-Botnia Study, UG (Germany) – KORA-gen (Germany), US (Sweden) – Malmo-Botnia 
Study; Hispanic: HA – San Antonio Family Heart Study, San Antonio Family Diabetes/ Gallbladder Study, 
Veterans Administration Genetic Epidemiology Study, and the Investigation of Nephropathy and Diabetes 
Study family component, HS – Starr County, Texas; South-Asian: SL – London Life Sciences Population 
Study, SS – Singapore Indian Eye Study.  
	  	  
 
Fig. S4: AKT family conservation compared to other genes. The dN/dS ratio (ratio of the number of non-
synonymous nucleotide substitutions per non-synonymous site and number of synonymous nucleotide 
substitutions per synonymous site) is calculated by comparing homologous coding sequences between human 
and chimpanzee. It indicates the degree to which selection is acting on a gene: ratio < 1 points to negative 
selection/purifying selection, i.e. evolutionary pressure to conserve the sequence in ancestral state, ratio > 1 to 
positive selection, and ratio = 1 to neutral evolution. The three AKT homologs, highlighted with arrows in the 
plot, are highly conserved when compared to the set of “Insulin monogenic” genes (37 genes), to which AKT2 
belongs, and two other gene sets: 1,002 anatomical structure development genes (“conserved”), and 132 
sexual reproduction genes (“fast evolving”). 
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Fig S5. Predicted structure change in AKT2 due to AKT2 p.Pro50Thr. The right plot shows the predicted 
structure of wild-type AKT2. The right plot shows the predicted structure of AKT2.Thr50. 
 
	  	  
 
Fig. S6. In vitro kinase (IVK) assay. Results of a generalized linear model (GLM) applied on rescaled raw 
data. The relative substrate phosphorylation values were generated by dividing each value in each round of 
analysis with the value for non-stimulated, serum-starved AKT2. A first GLM (“Round” model) was analyzed 
including the Round as variable; the three independent rounds were not significant: we used them as replicate 
in the Full model. The plots represent the GLM estimates (and 95% CI) in the Full model for the two significant 
interactions: A. Assay:Insulin. B. Assay:Variants. C. For the Glycogen Synthase Kinase 3 b (GSK3b), the 
different AKT2 variants show significant relative phosphorylation (pairwise comparison p-values from contrast 
analysis reported in inset table). For GST-GSK3 peptide, none of the AKT2 variants showed different relative 
phosphorylation values. * P < 0.05, ** P < 0.01, *** P < 0.001. DF: degrees of freedom, F: statistic testing the 
importance of the grouping term, Pr(>F): P value of the F statistic.  
A.#General#linear#analysis
#"Round"#model:
Variables DF
Variance-
explained-(%) F Pr(>F)
Round 2 2.73% 1.228 0.300
Assay 1 8.42% 7.572 0.008
Insulin7induction 1 12.38% 11.125 0.001
Round:Assay 2 1.60% 0.718 0.492
Round:Insulin 2 4.52% 2.033 0.140
Assay:Insulin 1 3.34% 2.999 0.088
Round:Assay:Insulin 2 0.27% 0.121 0.887
Full#model:
Variables DF
Variance-
explained-(%) F Pr(>F)
Assay 1 8.42% 14.71 3.12E;04
Insulin7induction 1 12.38% 21.61 1.98E;05
Variants 5 23.52% 8.21 6.49E;06
Assay:Insulin 1 3.34% 5.83 1.90E;02
Assay:Variant 5 19.13% 6.68 5.64E;05
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Fig. S7: Phosphorylation of AKT2 activation sites in HuH7 liver cells (A) HuH7 cells cells were infected 
with lentiviral V5-AKT2, V5-AKT2-Lys17, V5-AKT2-Thr50, V5-AKT2-Lys208, V5-AKT2-His274, V5-AKT2-
Trp467, starved for 18 hr (white bar), and stimulated for 20 min with 100nm insulin (grey bar). V5-tagged AKT2 
was isolated from cell lysates with anti-V5 agarose beads and immunoblots (IB) were probed with indicated 
antibodies. (B) Phosphorylated AKT2 Thr308 and Ser473 were quantified and normalized to total by V5-AKT2. 
(C) Linear model for the statistical analysis of quantified pAKT2. The “Round” model tests for significant 
differences between the three rounds of analysis. The Full model examines significance of assay (V5, pAKT2 
T308 and pAKT2 S473) and variants (AKT2, AKT2.Lys17, AKT2.Thr50, AKT2.Lys208, AKT2.His274 and 
AKT2.Trp467) and their interactions. * P < 0.05, ** P < 0.01, *** P < 0.001. DF: degrees of freedom, F: statistic 
testing the importance of the grouping term, Pr(>F): P value of the F statistic. 
General#linear#analysis
#"Round"#model:
Variables df
Variance-
explained-(%) F Pr(>F)
Round 2 1.86% 0.903 0.409
Assay 2 1.04% 0.504 0.606
Insulin8induction 1 2.00% 1.941 0.167
Round:Assay 4 0.20% 0.049 0.995
Round:Insulin 2 0.11% 0.055 0.946
Assay:Insulin 2 1.37% 0.664 0.517
Round:Assay:Insulin 4 0.63% 0.152 0.962
Full#model:
Variables df
Variance-
explained-(%) F Pr(>F)
Assay 2 1.04% 1.96 1.47E901
Variants 5 46.52% 35.13 2.20E916
Insulin8induction 1 2.00% 7.56 7.28E903
Assay:Variant 10 26.02% 9.83 8.39E911
Assay:Insulin 2 1.37% 2.59 8.11E@02
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Fig. S8. Time-course analysis of AKT2 phosphorylation (A) HeLa cells were infected with lentiviral V5-
AKT2, V5-AKT2-Thr50, or control pLX304, starved for 18 hours and then stimulated for 0, 2, 60, and 240 
minutes with 100nm insulin. V5-tagged AKT2 was isolated from cell lysates with anti-V5 agarose beads. 
Immunoprecipitated (IP) V5-AKT2 and whole cell lysates (WCL) were immunoblotted (IB) with the indicated 
antibodies.  Immunoblots are representative of three independent replicates. (B) Quantification of the three 
replicates of indicated immunoblots relative to total V5-AKT2. (C) Linear Model (LM) statistical analysis across 
all three independent replicates. Error bars represent the standard deviation (SD). * P < 0.05, ** P < 0.01, *** 
P < 0.001. 
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Fig. S9. Proliferation assay. A. Results of a generalized linear model (GLM) applied on rescaled raw data 
(absorbance value) to test for significant difference in proliferation between the three rounds of analysis, the 
three variants and an interaction between round and variants. The rescaling was performed by dividing all the 
values in each round by the average absorbance in controls. The plots represent the GLM estimates (and 95% 
CI) for the B. Round:Variant interaction and individual variables: C. Round and D. Variants. * P < 0.05, ** P < 
0.01, *** P < 0.001. DF: degrees of freedom, F: statistic testing the importance of the grouping term, Pr(>F): P 
value of the F statistic. 
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Fig. S10: AKT2 expression in human tissues. A. Boxplot displaying the level and distribution of AKT2 gene 
expression (in reads per kilobase per million mapped reads, RPKM) in 44 human tissues available in the GTEx RNA-
seq data. B. Box plot of the expression (in RNA-seq reads) of the AKT2 exon of affected by the p.Pro50Thr variant. 
Read counts are not normalized by the total number of reads per sample, resulting in larger variance in the expression 
within each tissue. C. Heat map of expression patterns of the 28 AKT2 transcripts in the GTEx tissues, as annotated in 
Gencode version 12. Intensity of color in each cell represents the expression of the transcript in that tissue; white 
indicating no expression, and red indicating higher expression. D. Visualization of the transcript structure of AKT2 
(Gencode v12). The affected exon, highlighted with the red dashed line, is included in the majority of the AKT2 
transcripts and in all the three most highly expressed transcripts. The tissues are presented in the same order across 
panels A-C, and colored similarly in panels A and B. Tissue abbreviations are listed in Table S4. 
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Fig. S11. Expression of the AKT gene family across human tissues. Each cluster of three boxplots 
represents the expression of AKT1 (left), AKT2 (middle) and AKT3 (right) in each tissue. AKT2 is the 
isoform with the highest expression (P-value < 0.05) in BRNCHA (Brain – Cerebellum), BRNCHB (Brain - 
Cerebellar Hemisphere), MSCLSK (Muscle – Skeletal) and PTTARY (Pituitary). Tissue abbreviations are listed 
in Table S4. 
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Increasing allele / 
decreasing alleles 
Frequency of 
decreasing 
allele 
Initial Effect 
of decreasing 
allele P     
Conditional 
Effect of 
decreasing 
allele 
Conditional 
P 
AKT2 Pro50Thr G/T 0.0083 -0.980 8.9E-04 -0.754 8.4E-03 
Lead eSNP 
rs8104727 T/C 0.647 -0.403 3.6E-14 -0.391 1.9E-13 
 
Fig S12: Expression analysis with common eQTL SNP and AKT2 p.Pro50Thr. Top left plot: The regional 
association plot of variants in the AKT2 region testing association with AKT2 expression. The SNP showing the 
most significant signal in this plot, rs8104727, is a proxy for rs11880261 (r2 = 1, D’ = 1 in the 1000 Genomes 
phase 3 Finnish sample). Top right plot: observed AKT2 expression levels for the two AKT2 p.Pro50Thr 
genotypes observed in the METSIM cohort. Bottom table: eQTL statistics and reciprocal conditional analysis 
with the two SNPs: rs8104727and AKT2 p.Pro50Thr. The “Beta conditional” and “P conditional” columns 
highlight the associations with AKT2 expression after conditioning on the other SNP. 
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Fig. S13: The trend in the estimate of the effect size of the global gene burden test for the four variant 
aggregation categories. The effect estimates (and 95% confidence interval) were provided as output of the 
burden test result in the RareMETALS package in R. 
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Fig. S14A: Monogenic enrichment in single variant association tests. Single variant association results 
from the FG and FI association analysis for variants in the four masks in the monogenic gene sets (top) and 
the insulin receptor signaling genes (bottom). 
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Fig. S14B: Pathway enrichment in gene-based tests. Gene burden association results from the fasting 
glucose and fasting insulin analysis for variants in the PTV+Missense mask in the monogenic gene sets (top) 
and the insulin receptor signaling genes (bottom). 
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Fig. S14C: Pathway associations in traits related to insulin resistance. Single variant association results 
for three traits related to insulin resistance: fasting adiponectin levels, 2 hour glucose level and 2 hour insulin 
level after an oral glucose tolerance test. The variants in these plots are in the PTV+Missense annotation 
category, with results from variants in the Monogenic gene sets (top) and the insulin receptor signaling genes 
(bottom). 
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Fig. S15A: Trait values among AKT2 variant carriers. Profile of the inverse normalized, adjusted metabolic 
trait values (top plot) and scaled raw trait values (bottom plot) of carriers of three AKT2 variants: AKT2 
p.Pro50Thr, AKT2 p.Arg208Lys and AKT2 p.Arg467Trp from the T2D-GENES whole exome sequencing data 
set.  Points on the graph are observed trait values for heterozygous (black) and homozygous (red) carriers of 
the variants, split by type 2 diabetes status. Trait abbreviations: HBA1C- glycated hemoglobin, FAST_INS- 
fasting insulin, FAST_GLU- fasting plasma glucose, TG- triglycerides, CHOL- total cholesterol, LDL-C, low-
density lipoprotein cholesterol, HDL-C- high-density lipoprotein cholesterol, BMI- body mass index, WHR- waist 
to hip ratio, WASITC- waist circumference, HIPC- hip circumference, DBP- diastolic blood pressure, SBP- 
systolic blood pressure. adjBMI- trait adjusted for BMI 
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Fig. S15B: Phenotype clustering of AKT2 missense variant carriers in the T2D-GENES whole exome 
sequencing dataset on seven metabolic traits: all missense carriers (A), carriers of AKT2 p.Pro50Ala variant 
(B), and carriers of the other variants (C), (see Supplementary Table 5). The row labels indicate the variant 
carried by an individual. P50Talleles: the number of Ala alleles carried; T2D: 0 for controls and 1 for type 2 
diabetics. 
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